HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Drug therapy for acquired pendular nystagmus in multiple sclerosis.

Abstract
Acquired pendular nystagmus (APN) is regularly accompanied by oscillopsia and impairment of static visual acuity. Therapeutic approaches to APN remain controversial, and there is no generally accepted therapeutic approach. We tested 14 patients who had suffered from APN caused by multiple sclerosis for several years; 12 patients presented with fixational pendular nystagmus (increasing during fixation) and 2 with spontaneous pendular nystagmus. All 11 patients with fixational pendular nystagmus who were given memantine, a glutamate antagonist, experienced complete cessation of the nystagmus. In contrast, scopolamine caused no (6 of 8) or only a minor (10-50%) reduction of the nystagmus (2 of 8). It was concluded that memantine is a safe treatment option for APN.
AuthorsM Starck, H Albrecht, W Pöllmann, A Straube, M Dieterich
JournalJournal of neurology (J Neurol) Vol. 244 Issue 1 Pg. 9-16 (Jan 1997) ISSN: 0340-5354 [Print] GERMANY
PMID9007739 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Excitatory Amino Acid Antagonists
  • Muscarinic Antagonists
  • Scopolamine Hydrobromide
  • Memantine
Topics
  • Adult
  • Electrooculography
  • Excitatory Amino Acid Antagonists (therapeutic use)
  • Female
  • Humans
  • Male
  • Memantine (adverse effects, therapeutic use)
  • Middle Aged
  • Multiple Sclerosis (complications)
  • Muscarinic Antagonists (therapeutic use)
  • Nystagmus, Pathologic (diagnosis, drug therapy)
  • Scopolamine Hydrobromide (adverse effects, therapeutic use)
  • Treatment Outcome
  • Visual Acuity (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: